PMID- 9876059
OWN - NLM
STAT- MEDLINE
DCOM- 19990303
LR  - 20131121
IS  - 1120-009X (Print)
IS  - 1120-009X (Linking)
VI  - 10
IP  - 6
DP  - 1998 Dec
TI  - Phase II study with ifosfamide, carboplatin, etoposide (ICE regimen) at 
      intermediate dosage for advanced non small cell lung cancer (NSCLC).
PG  - 492-5
AB  - We have evaluated the combination of ifosfamide, carboplatin and etoposide (ICE 
      regimen) along with mesna in 26 previously untreated patients with non small cell 
      lung cancer (NSCLC). Thirteen stage III B and 13 stage IV patients received 
      intermediate doses of ifosfamide (1000 mg/m2), carboplatin (120 mg/m2) and 
      etoposide (120 mg/m2) given intravenously on day 1 to 3 every 4 weeks. Except for 
      one patient who experienced grade 3 transient thrombocytopenia no major events of 
      hematological or systemic toxicity were observed. Response rate (27%, 95% C.I., 
      10 to 44%), median duration of response (9 months, range 6-15), and survival (9.5 
      months, range 2-44+) were comparable to those achieved with conventional 
      cisplatin-containing regimens. Our ICE combination, as compared to standard or 
      high dose schedules appears effective, safe, well tolerated, and devoid of severe 
      hematological toxicity.
FAU - Preti, P
AU  - Preti P
AD  - Divisione di Oncologia Medica, IRCCS Fondazione Salvatore Maugeri, Clinica del 
      Lavoro e della Riabilitazione, Pavia, Italy.
FAU - Poggi, G
AU  - Poggi G
FAU - Cuomo, A M
AU  - Cuomo AM
FAU - Robustelli della Cuna, F S
AU  - Robustelli della Cuna FS
FAU - Zambelli, A
AU  - Zambelli A
FAU - Pavesi, L
AU  - Pavesi L
LA  - eng
PT  - Clinical Trial
PT  - Clinical Trial, Phase II
PT  - Journal Article
PL  - England
TA  - J Chemother
JT  - Journal of chemotherapy (Florence, Italy)
JID - 8907348
RN  - 6PLQ3CP4P3 (Etoposide)
RN  - BG3F62OND5 (Carboplatin)
RN  - NR7O1405Q9 (Mesna)
RN  - UM20QQM95Y (Ifosfamide)
RN  - ICE protocol 5
SB  - IM
MH  - Adult
MH  - Aged
MH  - Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
MH  - Carboplatin/administration & dosage
MH  - Carcinoma, Non-Small-Cell Lung/drug therapy/pathology
MH  - Etoposide/administration & dosage
MH  - Female
MH  - Humans
MH  - Ifosfamide/administration & dosage
MH  - Lung Neoplasms/*drug therapy/pathology
MH  - Male
MH  - Mesna/administration & dosage
MH  - Middle Aged
MH  - Survival Analysis
MH  - Treatment Outcome
EDAT- 1999/01/06 00:00
MHDA- 1999/01/06 00:01
CRDT- 1999/01/06 00:00
PHST- 1999/01/06 00:00 [pubmed]
PHST- 1999/01/06 00:01 [medline]
PHST- 1999/01/06 00:00 [entrez]
AID - 10.1179/joc.1998.10.6.492 [doi]
PST - ppublish
SO  - J Chemother. 1998 Dec;10(6):492-5. doi: 10.1179/joc.1998.10.6.492.